Cardioprotection of Shenfu Injection (参附注射液) against myocardial ischemia/reperfusion injury in open heart surgery

Chuan-dong Zheng; Su Min

doi:10.1007/s11655-008-0010-y

Your Location：

Home >

Browse articles >

Cardioprotection of Shenfu Injection (参附注射液) against myocardial ischemia/reperfusion injury in open heart surgery

OriginalPaper | Updated：2021-08-27

- Cardioprotection of Shenfu Injection (参附注射液) against myocardial ischemia/reperfusion injury in open heart surgery
- Cardioprotection of Shenfu Injection (参附注射液) against myocardial ischemia/reperfusion injury in open heart surgery
- 中国结合医学杂志（英文版） 2008年14卷第1期页码：10-16
- Affiliations：
  
  1. Department of Anesthesiology, Sun Yat-sen University Tungwah Hospital,Dongguan,China
  2. Department of Anesthesiology, The First Affiliated Hospital, Chongqing University of Medical Sciences,Chongqing,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-008-0010-y
  中图分类号：
- 纸质出版日期：2008，
  
  网络出版日期：2008-6-21，
Scan for full text
Zheng, Cd., Min, S. Cardioprotection of Shenfu Injection (参附注射液) against myocardial ischemia/reperfusion injury in open heart surgery., Chin. J. Integr. Med. 14, 10–16 (2008). https://doi.org/10.1007/s11655-008-0010-y

Chuan-dong Zheng, Su Min. Cardioprotection of Shenfu Injection (参附注射液) against myocardial ischemia/reperfusion injury in open heart surgery[J]. Chinese Journal of Integrative Medicine, 2008,14(1):10-16.
Zheng, Cd., Min, S. Cardioprotection of Shenfu Injection (参附注射液) against myocardial ischemia/reperfusion injury in open heart surgery., Chin. J. Integr. Med. 14, 10–16 (2008). https://doi.org/10.1007/s11655-008-0010-y DOI：

Chuan-dong Zheng, Su Min. Cardioprotection of Shenfu Injection (参附注射液) against myocardial ischemia/reperfusion injury in open heart surgery[J]. Chinese Journal of Integrative Medicine, 2008,14(1):10-16. DOI： 10.1007/s11655-008-0010-y.

摘要

To investigate the protective effect of Shenfu Injection (参附注射液

SFI) against myocardium ischemia/reperfusion injury (IRI) in mitral valve replacement (MVR) with cardiopulmonary bypass (CPB). Forty patients undergoing selective MVR were randomly assigned to the control group and trial Groups I

III

and IV according to the different administrations of SFI

8 patients in each group. The changes of systolic blood pressure (SBP)

mean blood pressure (MBP)

diastolic blood pressure (DBP) in each group were monitored

respectively. The recovering percentage of spontaneous heart beat

the heart rate (HR) and cardiac rhythm as well as the abnormal duration of ECG-ST segment were recorded after the restoration of heart beat. The serum concentration of cardiac troponin I (cTnI)

malondialdehyde (MDA) and the activity of superoxide dismutase (SOD) were determined as well. (1) The SBP

MBP and DBP values

the recovering rate of spontaneous heart beat

ECG-ST

atrioventricular block and ventricular arrhythmia were significantly improved in group IV compared with any other groups. (2) Compared with the control group

the postoperative serum contents of cTnI and MDA were significantly decreased

but the activity of SOD was significantly increased in group IV. SFI had a certain protective effect against myocardium IRI. Moreover

better efficacy was seen with the administration of 1.5 mL/kg SFI into CPB priming fluid and pumping 1.5 mL/kg SFI via CPB as soon as the clamped aorta was unclamped.

Abstract

To investigate the protective effect of Shenfu Injection (参附注射液

III

and IV according to the different administrations of SFI

8 patients in each group. The changes of systolic blood pressure (SBP)

mean blood pressure (MBP)

diastolic blood pressure (DBP) in each group were monitored

respectively. The recovering percentage of spontaneous heart beat

the heart rate (HR) and cardiac rhythm as well as the abnormal duration of ECG-ST segment were recorded after the restoration of heart beat. The serum concentration of cardiac troponin I (cTnI)

malondialdehyde (MDA) and the activity of superoxide dismutase (SOD) were determined as well. (1) The SBP

MBP and DBP values

the recovering rate of spontaneous heart beat

ECG-ST

atrioventricular block and ventricular arrhythmia were significantly improved in group IV compared with any other groups. (2) Compared with the control group

the postoperative serum contents of cTnI and MDA were significantly decreased

but the activity of SOD was significantly increased in group IV. SFI had a certain protective effect against myocardium IRI. Moreover

better efficacy was seen with the administration of 1.5 mL/kg SFI into CPB priming fluid and pumping 1.5 mL/kg SFI via CPB as soon as the clamped aorta was unclamped.

关键词

Shenfu Injectioncardiopulmonary bypassmitral valve replacementmyocardial protectionischemia/reperfusion injury

Keywords

Shenfu Injectioncardiopulmonary bypassmitral valve replacementmyocardial protectionischemia/reperfusion injury

references

Shen YJ, ed. Pharmacology of Chinese herbal medicine. Beijing: People’s Medical Publishing House, 2000:862–863.

Chen DH, Li DX, Xu JH, et al. Effct of Shenfu Injection against shock. J Emerg Syndrome Tradit Chin Med (Chin) 2002;11(6):482–483.

He ZL, Yuan WH, Zou XL, et al. Effect of Shenfu Injection on patients with congestive heart failure and its mechanism. Chin J Integr Tradit West Med (Chin) 2001;21(5):386–387.

Zhai GL, Zhu HL, Jin J, et al. Effect of Shenfu Injection on the level of ox-LDL and NO in patients with coronary artery disease with angina pectoris. J Emerg Syndrome Tradit Chin Med (Chin) 2003;12(3):236.

Yang FJ, Zheng YS, Li DX, et al. Effect of Shenfu Injection on microcirculation. J Biomed Eng (Chin) 2003;20(1):91–94.

Li JX, Wang QZ, Zhong ZF, et al. Effect of Shenfu Injection on mexiletine ventricular premature beat. Chin J Integr Tradit West Med (Chin) 2002;22(5):394–395.

Liang WB. Effect of Shenfu Injection in high grade A-V block. Chin J Integr Tradit West Med Intens Crit Care (Chin) 1996;3(4):164–165.

Benoit MO, Paris M, Silleran J, et al. Cardiac troponin I: its contribution to the diagnosis of perioperative myocardial infarction and various complications of cardiac surgery. Crit Care Med 2001;10:1880–1886.

Lasocki S, Provenchere S, Benessiano J, et al. Cardiac troponin I is an independent predictor of in-hospital death after adult cardiac surgery. Anesthesiology 2002;2:405–411.

Vazquez-Jimenez JF, Qing M, Hermanns B, et al. Moderate hypothermia during cardiopulmonary bypass reduces myocardial cell damage and myocardial cell death related to cardiac surgery. J Am Coll Cardiol 2001;38:1216–1223.

Eigel P, van Ingen G, Wagenpfeil S. Predictive value of perioperative cardiac troponin I for adverse outcome in coronary artery bypass surgery. Eur J Cardiothorac Surg 2001;20:544–549.

Nesher N, Zisman E, Wolf T, et al. Strict thermoregulation attenuates myocardial injury during coronary artery bypass graft surgery as reflected by reduced levels of cardiacspecific troponin I. Anesth Analg 2003;96:328–335.

Wan S, Yim AP, Wong CK, et al. Expression of FHL2 and cytokine messenger RNAs in human myocardium after cardiopulmonary bypass. Intl J Cardiol 2002;86:265–272.

Vermes E, Mesguich M, Houel R, et al. Cardiac troponin I release after open heart surgery: a marker of myocardial protection? Ann Thorac Surg 2000;70:2087–2090.

Montgomery VL, Sullivan JE, Buchino JJ. Prognostic value of pre-and postoperative cardiac troponin I measurement in children having cardiac surgery. Pediatr Dev Pathol 2000;3:53–60.

Bimmel D, Patermann B, Schlosser T, et al. Do we still need CK-MB in coronary artery bypass grafting surgery? J Cardiovasc Surg (Torino) 2003;44:191–196.

Belboul A, Roberts D, Borjesson R, et al. Oxygen free radical generation in healthy blood donors and cardiac patients: the protective effect of allopurinol. Perfusion 2001;16:59–65.

Blaszczyk J, Kedziora J, Zaslonka J, et al. Moderate systemic hypothermia and cold crystalloid cardioplegia influence on myocardial ischemic and revascularisative injury. Med Sci Monit 2000;6:981–988.

Prasad K, Chan WP, Bharadwaj B. Superoxide dismutase and catalase in protection of cardiopulmonary bypassinduced cardiac dysfunction and cellular injury. Can J Cardiol 1996;12:1083–1091.

Inal M, Alatas O, Kural T, et al. Oxygen free radicals in erythrocytes during open heart operation. J Cardiovasc Surg (Torino) 1994;35:147–150.

Pias EK, Ekshyyan OY, Rhoads CA, et al. Differential effects of superoxide dismutase isoform expression on hydroperoxide-induced apoptosis in PC-12 cells. J Biol Chem 2003;278:13294–13301.

Sugino N, Karube Harada A, Sakata A, et al. Different mechanisms for the induction of copper-zinc superoxide dismutase and manganese superoxide dismutase by progesterone in human endometrial stromal cells. Hum Reprod 2002;17:1709–1714.

Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 2002;33:337–349.

Suzuki K, Murtuza B, Sammut IA, et al. Heat shock protein 72 enhances manganese superoxide dismutase activity during myocardial ischemia-reperfusion injury, associated with mitochondrial protection and apoptosis reduction. Circulation 2002;106(12 Suppl 1):1270–1276.

Asimakis GK, Lick S, Patterson C. Postischemic recovery of contractile function is impaired in SOD2(+/-) but not SOD1(+/-) mouse hearts. Circulation 2002;105:981–986.

Liu XY, Zou HD, Yu JP, et al. Protective effect of Shen-Fu Injection on multiple organ damage in rabbit during ischemia reperfusion. Chin J Anaesthesiol (Chin) 1997;17(7):430–432.

FULL TEXT LINK

More>

浏览量

355

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Neuroprotective effect of Shenfu Injection (参附注射液) following cardiac arrest in pig correlates with improved mitochondrial function and cerebral glucose uptake

Therapeutic effects of shenfu injection (参附注射液) on post-cardiac arrest syndrome

Neutroprotective efficacy of sodium tanshinone B on hippocampus neuron in a rat model of focal cerebral ischemia

Role of Shenfu Injection (参附注射液) in rats with systemic inflammatory response syndrome

Improvement of quality of life with Shenfu injection in non small cell lung cancer patients treated with gemcitabine plus cisplatin regimen